so patient Phase IIB trial in TN, stratified by HG
That's another approach as well. I agree they shouldn't abandon TN without HG due to lack to treatment option. The small number in subgroup analysis could easily skew result. You and I are generally in agreement here, the signal is there, needs to have larger trial and more comprehensive development plan from now on.
Market Data 
Markets 
AI
